NCM
TSHA icon

Nantahala Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Nantahala Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,251,139
Closed -$827K – 145
2023
Q2 		$827K Sell
1,251,139
-471,261
-27% -$341K 0.08% 97
2023
Q1 		$1.35M Sell
1,722,400
-1,277,365
-43% -$1.65M 0.1% 90
2022
Q4 		$6.78M Buy
2,999,765
+1,388,943
+86% +$2.81M 0.44% 46
2022
Q3 		$3.25M Sell
1,610,822
-32,616
-2% -$118K 0.21% 60
2022
Q2 		$6.11M Buy
1,643,438
+309,491
+23% +$1.23M 0.31% 56
2022
Q1 		$8.7M Sell
1,333,947
-122,200
-8% -$913K 0.38% 48
2021
Q4 		$17M Buy
1,456,147
+206,838
+17% +$3.12M 0.6% 38
2021
Q3 		$23.3M Buy
1,249,309
+817,237
+189% +$15.5M 0.73% 36
2021
Q2 		$9.16M Buy
432,072
+395,116
+1,069% +$9.11M 0.26% 78
2021
Q1 		$750K Sell
36,956
-41,620
-53% -$1.13M 0.02% 111
2020
Q4 		$2.08M Buy
78,576
+3,576
+5% +$77K 0.06% 100
2020
Q3 		$1.68M Buy
+75,000
New +$1.76M 0.05% 102

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Nantahala Capital Management's TSHA Position: Q3 2023 in Review

Nantahala Capital Management sold out of Taysha Gene Therapies (TSHA) in Q3 2023, closing a stake of 1,251,139 shares — an estimated $827K sold.

Nantahala Capital Management first reported a position in TSHA in Q3 2020 and held it in 12 quarters. The position peaked at $23.3M in Q3 2021. 63 funds tracked by Wall St. Rank hold TSHA as of Q3 2023.

  • Nantahala Capital Management reported no remaining Taysha Gene Therapies position as of Q3 2023 after selling out during the quarter.
  • Nantahala Capital Management sold 1,251,139 Taysha Gene Therapies shares in Q3 2023, an estimated $827K.
  • Nantahala Capital Management first reported a position in Taysha Gene Therapies in Q3 2020 and held it in 12 quarters.
  • Nantahala Capital Management's Taysha Gene Therapies position peaked at $23.3M in Q3 2021.
  • 63 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2023.

Based on Nantahala Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.